Dean Rudge
Deputy Editor
Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest From Dean Rudge
Coherus: Udenyca Trajectory ‘Unknown’ But ‘Compelling’ With On-Body Launch
Coherus BioSciences has spoken in detail about its full suite of Udenyca pegfilgrastim biosimilar products and how it plans to return to growth and positive cash flow moving forward – although it cannot, for now, provide an estimate for 2024 revenues.
Stada Set To Minimize Xbrane Ownership As Swedish Firm Hunts For Cash
“We are extremely well aware of the consequences for investors that cannot protect their ownership share in this transaction,” Xbrane has told its investors, as the Swedish firm looks to tie up much-needed capital injection via a right issue to fuel its pipeline of biosimilar projects.
Viatris And Mapi Knocked Back On Once-Monthly US Copaxone Rival
Viatris offered little in the way of detail as it announced a setback for its Mapi Pharma-partnered proposed once-monthly glatiramer acetate product for relapsing forms of multiple sclerosis. The firm has previously shouted from the rooftops about Mapi’s Phase III clinical study and the potential to establish a new standard of care for glatiramer acetate patients.
Richter On Formycon Investment: ‘Indispensable’ To Partner On Everything We Do
Fledgling biosimilars player Gedeon Richter has spoken candidly and openly with investors on its recent biosimilar investments, its goal to start generate cash from its young Biotech business, and its need to manage costs in order to make that happen.
Sandoz Swallows Up Remainder Of Rowex To ‘Expand Fully’ Into Ireland
Sandoz has a goal of increasing generic penetration in Ireland, which lags behind its European neighbors. As part of that objective, the firm has opted to take full control of its Rowex joint venture, based in County Cork.
Richter Takes Control Of German JVs To Wrap Up Teriparatide Biosimilar
Gedeon Richter is putting its hand back in its wallet following its recent investment in Formycon, opting to take control of a pair of joint ventures established with German firm Helm.